Wright Moves More To Extremes With Tornier Purchase Agreement
This article was originally published in The Gray Sheet
Executive Summary
The all-stock transaction valued at around $3.3 billion will create a device and biologics company with a comprehensive focus on orthopedic extremities surgery. The firms expect cost synergies of $40 to $45 million.